Keyword Index

A

  • Alpha fetoprotein Incidence of hepatocellular carcinoma one year after direct acting antiviral therapy for treatment of HCV infection in patients with decompensated liver cirrhosis; A multicenter study [6.2, Issue 2, 2022, Pages 11-17]

C

  • Castleman disease Castleman disease as an unusual cause of ascites : Case report [6.2, Issue 2, 2022, Pages 1-3]

D

  • Direct-acting antiviral agents Incidence of hepatocellular carcinoma one year after direct acting antiviral therapy for treatment of HCV infection in patients with decompensated liver cirrhosis; A multicenter study [6.2, Issue 2, 2022, Pages 11-17]

E

  • Endoscopy Platelet count/spleen diameter ratio as a predictor of high-risk esophageal varices in patients with liver cirrhosis [6.2, Issue 2, 2022, Pages 25-30]
  • Enzyme replacement therapy and hepatosplenomegaly Gaucher disease: Recent advances in the diagnosis and management. [6.2, Issue 2, 2022, Pages 6-10]
  • Esophageal varices Platelet count/spleen diameter ratio as a predictor of high-risk esophageal varices in patients with liver cirrhosis [6.2, Issue 2, 2022, Pages 25-30]

G

  • Gaucher disease Gaucher disease: Recent advances in the diagnosis and management. [6.2, Issue 2, 2022, Pages 6-10]

H

  • Hepatitis C virus Incidence of hepatocellular carcinoma one year after direct acting antiviral therapy for treatment of HCV infection in patients with decompensated liver cirrhosis; A multicenter study [6.2, Issue 2, 2022, Pages 11-17]
  • Hepatocellular carcinoma Incidence of hepatocellular carcinoma one year after direct acting antiviral therapy for treatment of HCV infection in patients with decompensated liver cirrhosis; A multicenter study [6.2, Issue 2, 2022, Pages 11-17]
  • Hepatocellular carcinoma Diagnostic value of of Long Non-Coding RNA ZFAS1 as a Potential Biomarker for Hepatocellular Carcinoma [6.2, Issue 2, 2022, Pages 18-24]

L

  • Liver cirrhosis Diagnostic value of of Long Non-Coding RNA ZFAS1 as a Potential Biomarker for Hepatocellular Carcinoma [6.2, Issue 2, 2022, Pages 18-24]
  • Liver cirrhosis Platelet count/spleen diameter ratio as a predictor of high-risk esophageal varices in patients with liver cirrhosis [6.2, Issue 2, 2022, Pages 25-30]

M

  • Metabolic Metabolic Associated Fatty Liver Disease as the New Nomenclature for Nonalcoholic Fatty Liver Disease [6.2, Issue 2, 2022, Pages 4-5]
  • Metabolic associated fatty liver disease Metabolic Associated Fatty Liver Disease as the New Nomenclature for Nonalcoholic Fatty Liver Disease [6.2, Issue 2, 2022, Pages 4-5]

N

  • Nomenclature Metabolic Associated Fatty Liver Disease as the New Nomenclature for Nonalcoholic Fatty Liver Disease [6.2, Issue 2, 2022, Pages 4-5]
  • Nonalcoholic fatty liver disease Metabolic Associated Fatty Liver Disease as the New Nomenclature for Nonalcoholic Fatty Liver Disease [6.2, Issue 2, 2022, Pages 4-5]
  • Non-Coding RNA ZFAS1 Diagnostic value of of Long Non-Coding RNA ZFAS1 as a Potential Biomarker for Hepatocellular Carcinoma [6.2, Issue 2, 2022, Pages 18-24]

S

  • Sustained virologic response Incidence of hepatocellular carcinoma one year after direct acting antiviral therapy for treatment of HCV infection in patients with decompensated liver cirrhosis; A multicenter study [6.2, Issue 2, 2022, Pages 11-17]